- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03693872
Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals (AGAPO)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The recruitment period will be 24 months. The duration of the study will be 6 months for each patient due to adjustments of apomorphine pump parameters and oral medication as well time needed for motor and nonmotor changes to develop and influence QoL.
This study will be done without any modification of the planned treatment plan for each patient included. The treatments are administered in accordance with their marketing authorization and according to the usual practices of each center. No additional visits are expected.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Marc VERIN, PH
- Phone Number: +33 299289842
- Email: marc.verin@chu-rennes.fr
Study Contact Backup
- Name: Manon Auffret
Study Locations
-
-
-
Montpellier, France, 34295
- Hopital Gui de Chauliac
-
Nîmes, France, 30029
- CH Caremeau
-
Paris, France, 75013
- CHU La Pitié Salpêtrière
-
Reims, France, 51100
- CHU de Reims- hôpital Maison Blanche
-
Rennes, France, 35033
- Chu de Rennes
-
Rouen, France, 76000
- Chu Charles Nicolle
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults aged = or > 18 years,
- Idiopathic PD (According to British Brain Bank Criteria) without any other known or suspected cause of symptoms,
- Indicated for apomorphine pump therapy and according to the centers' practice, treatment with apomorphine pump association with dopamine agonists or apomorphine pump therapy alone
- Presence of fluctuations for > 3 years,
- Patients covered with social insurance.
- Written informed consent
Exclusion Criteria:
- Neurological (other than Parkinson's disease) or severe psychiatric history (depression, schizophrenia, addiction, bipolar disorder, anxiety and depressive disorders);
- Severe neurocognitive disorders (DSM-V)
- History of use of apomorphine pump treatment or deep brain stimulation or lesional surgery for PD or intrajejunal L-Dopa;
- History or current drug or alcohol abuse or dependencies;
- History of impulse control disorders;
- Adults legally protected (under judicial protection, guardianship or supervision), persons deprived of their liberty;
- Inability to understand the information given on the study, to express informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Apomorphine
Withdrawal of dopaminergic agonists at pump initiation
|
Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient
Other Names:
|
Other: Dopaminergic Agonist + Apomorphine
Continuation of dopaminergic agonists at pump initiation
|
Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient and associated with dopaminergic agonists
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in the Non Motor Symptoms Scale (NMSS) between the Baseline assessment and the assessment at 6 months' follow up
Time Frame: 6 months
|
The Non-Motor Symptoms Scale (NMSS) measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease, through 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating).
Severity is rated on a scale from 0 (none) to 3 (severe).
Frequency is rated on a scale from 1 (rarely) to 4 (very frequent).
Item scores are calculated as the product of severity and frequency; the total score is obtained by summing the item scores.
The NMSS total score ranges from 0 to 360 with a lower score indicating fewer symptoms.
A negative change from baseline indicates improvement in symptoms (reduced score).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Parkinson's Disease Quality of Life Questionnaire (PDQ39) between the Baseline assessment and the assessment at 6 months' follow up
Time Frame: 6 months
|
Parkinson's Disease Quality of Life Questionnaire (PDQ-39): the 39-Item Parkinson's Disease Questionnaire (PDQ-39) is a commonly used measure of self-appraisal in PD.
It is a measure of health status and quality of life, by assessing difficulties in 8 dimensions of daily living: mobility (10 items), activities of daily living (6 items), emotional well-being (6 items), stigma (4 items), social support (3 items), cognition (4 items), communication (3 items) and bodily discomfort (3 items).
The frequency of each event is determined by selecting one of 5 options: never (scored 0) / occasionally (scored 1) / sometimes (2) / often (3) / always (4).
Each dimension total score range from 0 to 100, with lower scores reflecting better quality of life.
|
6 months
|
Change in the Neurologist Global Impression of change (CGI) between the Baseline assessment and the assessment at 6 months' follow up
Time Frame: 6 months
|
The Change in the Neurologist (clinician) Global Impression of change (CGI) provides a brief, stand-alone assessment of the clinician's view of the patient's global functioning prior to and after initiating a study medication.
It ranges from severely impaired to dramatically improved.
|
6 months
|
Change in non-motor aspects of experiences of daily living (MDS-UPDRS I) between the Baseline assessment and the assessment at 6 months' follow up
Time Frame: 6 months
|
The Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is the standard validated tool for the assessment of patients with Parkinson's Disease (PD).
This combined scale includes subsections collecting data regarding: nonmotor experiences of daily living (part I), their motor experiences of daily living (part II) an examination of the motor features of PD (part III), and motor complications arising from the use of dopamine replacement (part IV).
The Part I include 13 items (6 semistructured interview items and 7 self-reported items) scored on a scale from 0 (normal) to 4 (severe).
Higher scores reflect worse condition.
|
6 months
|
Change in apathy assessed on the long version of Lille Apathy Rating Scale between the Baseline assessment and the assessment at 6 months' follow up (LARS)
Time Frame: 6 months
|
The Lille apathy rating scale (LARS) is a measure of apathy through nine domains (each corresponding to a clinical manifestation of apathy: everyday productivity, interests, taking the initiative, novelty seeking, motivation - Voluntary actions, emotional responses, concern, social life & self-awareness) and 33 queries.
The interview is structured, with a precise scoring mode for each reply (-2 to 2); when an item does not apply to the patient or the reply cannot be classified, it is scored "0" (for non-applicable and/or non-classifiable) The scale's overall score ranges from -36 to +36, with highest scores reflecting apathy severity.
4 factorial sub-scores (intellectual curiosity, emotion, action initiation and self-awareness) are calculated from sub-scale scores.
|
6 months
|
Change in occurrence of anxiety (STAI-YA) between the Baseline assessment and the assessment at 6 months' follow up
Time Frame: 6 months
|
Present feelings
|
6 months
|
Change in occurrence of anxiety (STAI-YB) between the Baseline assessment and the assessment at 6 months' follow up
Time Frame: 6 months
|
General feelings
|
6 months
|
Change in behavioral symptoms assessed by Ardouin Scale between the Baseline assessment and the assessment at 6 months' follow up
Time Frame: 6 months
|
Changes from baseline in hyper and hypo dopaminergic symptoms scores will be assessed through the Ardouin Scale of Behavior in Parkinson's Disease (ASBPD).
It is designed for assessing mood and behavior with a view to quantifying changes related to Parkinson's disease, to dopaminergic medication, and to non-motor fluctuations.
Its 21 items address nonmotor symptoms and are grouped into four dimensions: general psychological assessment, apathy, nonmotor fluctuations and hyperdopaminergic behaviors, with a 5-point rating scale ranging from 0 (Absent) to 4 (Severe).
A score ≥ 2 is considered as a warning sign.
|
6 months
|
Change in emotional function assessed by the short form of the TEIQue between the Baseline assessment and the assessment at 6 months' follow upscale
Time Frame: 6 months
|
The Trait Emotional Intelligence Questionnaire-Short Form (TEIQue-SF) aims at evaluating emotional intelligence through a self-report inventory that measure global trait emotional intelligence (trait EI) through a 30-item questionnaire.
The trait EI is about perceptions and not about abilities, competencies or skills ; high scores are not necessarily adaptive (good) and low scores are not necessarily maladaptive (bad).
|
6 months
|
Change in emotional function assessed by the short form of the BEQ scale between the Baseline assessment and the assessment at 6 months' follow up
Time Frame: 6 months
|
The Berkeley Expressivity Questionnaire (BEQ) is a self-report measure of three emotional expressivity facets related to emotional expressivity: expressivity of negative and positive emotions, and strength of expression impulse.
Each of the 16 items is answered on a 7-point Likert-type ranging from 1 (strongly disagree) to 7 (strongly agree).
The 3 facets can be kept as separate scores or combined to form an overall Emotional Expressivity score.
|
6 months
|
Change in motor aspects of experiences of daily in "on" and "off" medication (MDS-UPDRS II) between the Baseline assessment and the assessment at 6 months' follow up
Time Frame: 6 months
|
The Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is the standard validated tool for the assessment of patients with Parkinson's Disease (PD).
This combined scale includes subsections collecting data regarding: nonmotor experiences of daily living (part I), their motor experiences of daily living (part II) an examination of the motor features of PD (part III), and motor complications arising from the use of dopamine replacement (part IV).
The Part II include 13 self-reported items) scored on a scale from 0 (normal) to 4 (severe).
Higher scores reflect worse condition.
|
6 months
|
Change in motor examination during "on" periods (MDS-UPDRS III) between the Baseline assessment and the assessment at 6 months' follow up
Time Frame: 6 months
|
The Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is the standard validated tool for the assessment of patients with Parkinson's Disease (PD).
This combined scale includes subsections collecting data regarding: nonmotor experiences of daily living (part I), their motor experiences of daily living (part II) an examination of the motor features of PD (part III), and motor complications arising from the use of dopamine replacement (part IV).
The Part III include 18 items scored on a scale from 0 (normal) to 4 (severe).
Higher scores reflect worse condition.
|
6 months
|
Change in motor complications with MDS-UPDRS IV between the Baseline assessment and the assessment at 6 months' follow up
Time Frame: 6 months
|
The Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is the standard validated tool for the assessment of patients with Parkinson's Disease (PD).
This combined scale includes subsections collecting data regarding: nonmotor experiences of daily living (part I), their motor experiences of daily living (part II) an examination of the motor features of PD (part III), and motor complications arising from the use of dopamine replacement (part IV).
The Part IV include 6 items assessed in a semistructured interview, scored on a scale from 0 (normal) to 4 (severe).
Higher scores reflect worse condition.
|
6 months
|
Change in motor examination with the Schwab and England scale between the Baseline assessment and the assessment at 6 months' follow up
Time Frame: 6 months
|
The Schwab & England activities of daily living evaluates patients' autonomy through a percentage ranging from 0% (=Vegetative functions such as swallowing, bladder and bowel functions are not functioning. Bedridden.) to 100% ( = Completely independent. Able to do all chores without slowness, difficulty or impairment. Essentially normal). Unaware of any difficulty. |
6 months
|
Change in motor examination with the Hoehn & Yarr scale
Time Frame: 6 months
|
The severity of PD is assessed through the Modified Hoehn & Yahr rating scale, consisting of 10levels comprised between 0 (best), 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5 (worst).
|
6 months
|
Change in cognitive function assessed by the MoCA scale between the Baseline assessment and the assessment at 6 months' follow up
Time Frame: 6 months
|
The Montreal Cognitive Assessment (MoCA) is a short tool (one-page 30-point test administered in approximately 10 minutes) to evaluate a multitude of cognitive domains (visuospatial / executive functioning, object naming, memory, attention, language, abstraction, orientation).
MoCA scores range between 0 and 30; a score ≥ 26 is considered to be normal.
|
6 months
|
Change of dose for treatments assessed by levodopa (L-DOPA) équivalents between the Baseline assessment and the assessment at 6 months' follow up
Time Frame: 6 months
|
6 months
|
|
Frequency, type and severity of therapy-related adverse events
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marc VERIN, PH, Rennes University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Gastrointestinal Agents
- Protective Agents
- Cardiotonic Agents
- Dopamine Agents
- Sympathomimetics
- Emetics
- Apomorphine
- Dopamine
- Dopamine Agonists
Other Study ID Numbers
- 35RC18_9721_AGAPO
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Apomorphine
-
SunovionCompletedMotor OFF Episodes Associated With Parkinson's DiseaseSpain, United Kingdom, Germany, Italy, Austria, France
-
University Hospital, ToulouseCompletedParkinson's DiseaseFrance
-
University Hospital, RouenRecruitingPatients With Parkinson's Disease Treated With Apomorphine PumpsFrance
-
Oregon Health and Science UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Withdrawn
-
Alexza Pharmaceuticals, Inc.ISS, Inc.; DSG; Peachtree BioResearch SolutionsTerminated
-
Mylan Bertek PharmaceuticalsCompleted
-
Mylan Bertek PharmaceuticalsCompletedParkinson DiseaseUnited States
-
Hospital Universitari Vall d'Hebron Research InstituteUnknown
-
Mylan Bertek PharmaceuticalsCompleted
-
Britannia Pharmaceuticals Ltd.CompletedParkinson's Disease